Innovent
Innovent including oncology
Innovent is a leading biotechnology company in China. It aims to produce highly complex and affordable biopharmaceutical products for patients. Since its inception, Innovent has established a product chain of 13 new drugs covering four major disease areas, including oncology, ophthalmology, autoimmune diseases and cardiovascular diseases, and has undertaken 7 National Science and Technology Projects, of which 5 products were selected for the National "Major New Drug Creation" Program and 1 product was selected for the National Key Research and Development Program. Special "Precision Medicine Research".
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Levostar Completes Pre-A Financing Round to Further Invest in CGT
BlissBio Nets Over CNY 100 Mn in Series B+
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
NaviSeed Nets Tens of millions of CNY in Angel Round
Nuwacell Nets Hundreds of Mns of CNY in Series A
SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year
EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.
Jun 06, 2024 06:18 PM
Enitiatebio Nets One Hundred Million of CNY in Series A Round
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Cinda biology and Baoyuan medicine announced that taretinib was included in the breakthrough therapeutic drug variety
Xinda biology and JinFang medicine have reached global strategic cooperation on KRAS G12C inhibitor gfh925